🔎 Trials Near Me

Home › Wilms Tumor › New York

Pag-aaral pangklinika para sa Wilms Tumor sa New York

6 pag-aaral para sa Wilms Tumor ang naghahanap ng mga kalahok sa mga site sa New York.

Mga Lungsod sa New York

Opisyal na teksto ng pag-aaral (English)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • New York Medical College, Valhalla
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT04616560

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • Albany Medical Center, Albany
  • Roswell Park Cancer Institute, Buffalo
  • The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
  • at 9 pa
Nagre-recruitPhase 2
Hanggang edad 30 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04322318

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activites), New York
  • at 1 pa
Nagre-recruitPhase 2
12 Months · Lahat ng kasarian · Na-update May 6, 2026 · NCT05985161

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

  • New York Medical College, Valhalla
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04308330

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  • Children's Hospital at Montefiore, The Bronx
Nagre-recruitPhase 2
18 Months – 40 Years · Lahat ng kasarian · Na-update Ago 12, 2025 · NCT05135975

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.